Brief: Disc Medicine Provides Update On Hematology Portfolio
20/10/2025 11:38
Oct 20 (Reuters) - Disc Medicine Inc IRON.O: DISC MEDICINE PROVIDES UPDATE ON HEMATOLOGY PORTFOLIO AND OUTLINES NEAR-TERM BUSINESS OBJECTIVES AND ANTICIPATED MILESTONES DISC MEDICINE INC - INITIAL DATA FROM PHASE 2 STUDY IN ANEMIA OF MF BY YEAR END, TOPLINE DATA EXPECTED IN 2026 DISC MEDICINE INC - PHASE 1B STUDY IN PATIENTS WITH SCD ANTICIPATED BY YEAR END DISC MEDICINE INC: PHASE 2 STUDY IN PATIENTS WITH IBD AND ANEMIA ANTICIPATED IN Q1 2026 DISC MEDICINE INC: ACCELERATING EFFORTS FOR POTENTIAL EARLIER APPROVAL AND COMMERCIALIZATION OF BITOPERTIN FOR EPP IN US DISC MEDICINE INC: APPROVAL AND COMMERCIALIZATION OF BITOPERTIN FOR EPP IN US EXPECTED IN LATE 2025 OR EARLY 2026 Source text: ID:nGNXbkSnrM Further company coverage: IRON.O ((((Reuters.Briefs@thomsonreuters.com));))